SCHEMBL5610091

SCHEMBL5610091

COc1ccc(CCC[S])cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.62
TAAR1 Q96RJ0 1/20 0.57
IGF1R P08069 1/20 0.55
ALOX15 P16050 1/20 0.55
MAOB P27338 2/20 0.52
ALOX5 P09917 1/20 0.51
IDO1 P14902 1/20 0.50
SIGMAR1 Q99720 1/20 0.50
AOC3 Q16853 1/20 0.50
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
F2RL1 P55085 1/20 0.48
TUBB4A P04350 1/20 0.48
TUBB P07437 1/20 0.48
TUBA3C P0DPH7 1/20 0.48
TUBA1B P68363 1/20 0.48
TUBA4A P68366 1/20 0.48
TUBB4B P68371 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5609202 0.94 CALM1 (0.60) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL5609660 0.86 TAAR1 (0.61) CALM1TAAR1MAOBIDO1SIGMAR1
SCHEMBL244070 0.86 CALM1 (0.79) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL4254058 0.86 CALM1 (0.72) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL10571532 0.84 CALM1 (0.69) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL11007798 0.84 CALM1 (0.69) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL9509173 0.84 CALM1 (0.69) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL17400406 0.84 CALM1 (0.69) CALM1TAAR1IGF1RALOX15MAOB
SCHEMBL834551 0.81 TAAR1 (0.73) CALM1TAAR1MAOBIDO1SIGMAR1
SCHEMBL10569081 0.80 MAOB (0.70) CALM1TAAR1IGF1RALOX15MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199139-B2 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
EP-1354602-B1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT SANKYO CO (JP) 2006-10-04 EP disclosed
EP-1695716-A2 Medicinal compositions containing diuretics and insulin sensitizers Sankyo Company, Limited (JP) 2006-08-30 EP disclosed
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2005-12-29 US disclosed
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent SANKYO COMPANY, LIMITED (JP) 2004-03-18 US disclosed
EP-1354602-A1 MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT Sankyo Company, Limited (JP) 2003-10-22 EP disclosed
EP-0916651-B1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES SANKYO CO (JP) 2003-10-15 EP disclosed
US-6103907-A ALDOSE REDUCTASE INHIBITING ANTIDIABETIC AGENT SANKYO COMPANY, LIMITED (JP) 2000-08-15 US disclosed
EP-0916651-A1 PHENYLALKYLCARBOXYLIC ACID DERIVATIVES Sankyo Company, Limited (JP) 1999-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053974-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 CALM1 1156/4885TAAR1 3666/4885IGF1R 9/4885
US-20050288339-A1 Medicinal compositions containing diuretic and insulin resistance-improving agent GPR119, INSR, IRS1 CALM1 1156/4885TAAR1 3666/4885IGF1R 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.